| scholarly article | Q13442814 |
| P2093 | author name string | Andreas Friedl | |
| Kristy Meyer | |||
| Christoph Mundhenke | |||
| Sally Drew | |||
| P2860 | cites work | Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization | Q24290400 |
| Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin | Q24290496 | ||
| Receptor specificity of the fibroblast growth factor family | Q24320178 | ||
| Fibroblast growth factors | Q24542507 | ||
| The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer | Q24564355 | ||
| Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4 | Q24681644 | ||
| Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells | Q28206492 | ||
| Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2 | Q28273441 | ||
| Regulated diversity of heparan sulfate | Q28282444 | ||
| Fibroblast growth factors as multifunctional signaling factors | Q28283514 | ||
| Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation | Q28296150 | ||
| Specificities of heparan sulphate proteoglycans in developmental processes | Q28377841 | ||
| Control of morphology, cytoskeleton and migration by syndecan-4 | Q28568063 | ||
| Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface-associated syndecans and glypican | Q28633960 | ||
| Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor | Q29616189 | ||
| Sequencing complex polysaccharides | Q30791276 | ||
| Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity | Q32030968 | ||
| Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. Further evidence for heparan sulfate heterogeneity in the kidney | Q32064386 | ||
| Human HST1 (HSTF1) gene maps to chromosome band 11q13 and coamplifies with the INT2 gene in human cancer | Q33586168 | ||
| FGF signals for cell proliferation and migration through different pathways | Q34013838 | ||
| Examination of the substrate specificity of heparin and heparan sulfate lyases | Q34324156 | ||
| A strategy for rapid sequencing of heparan sulfate and heparin saccharides | Q35059120 | ||
| The role of fibroblast growth factors and related oncogenes in tumor growth | Q35168748 | ||
| Differential binding of fibroblast growth factor-2 and -7 to basement membrane heparan sulfate: comparison of normal and abnormal human tissues | Q35764272 | ||
| Developmental changes in heparan sulfate expression: in situ detection with mAbs | Q36532134 | ||
| Mouse Mammary Tumor Virus Integration Regions int-1 and int-2 Map on Different Mouse Chromosomes | Q36941611 | ||
| Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4 | Q38314349 | ||
| Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells | Q38331586 | ||
| Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate | Q38338357 | ||
| Two hierarchies of FGF-2 signaling in heparin: mitogenic stimulation and high-affinity binding/receptor transphosphorylation. | Q38353810 | ||
| Activation of an enhancer on the syndecan-1 gene is restricted to fibroblast growth factor family members in mesenchymal cells | Q40022347 | ||
| The role of syndecan cytoplasmic domain in basic fibroblast growth factor-dependent signal transduction | Q40935731 | ||
| Differential responsiveness of human breast cancer cells to basic fibroblast growth factor: a cell kinetics study | Q41385014 | ||
| MDA-MB-134 breast carcinoma cells overexpress fibroblast growth factor (FGF) receptors and are growth-inhibited by FGF ligands. | Q41494534 | ||
| Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis | Q42476789 | ||
| Tissue-specific binding by FGF and FGF receptors to endogenous heparan sulfates | Q43671611 | ||
| Basic fibroblast growth factor (bFGF): mitogenic activity and binding sites in human breast cancer | Q45153199 | ||
| Extracellular matrix-dependent activation of syndecan-1 expression in keratinocyte growth factor-treated keratinocytes | Q47905709 | ||
| Developmental Regulation of Neural Response to FGF-1 and FGF-2 by Heparan Sulfate Proteoglycan | Q52225676 | ||
| Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. | Q53437765 | ||
| Differential Regulation of FGF-1 and -2 Mitogenic Activity Is Related to Their Kinetics of Binding to Heparan Sulfate in MDA-MB-231 Human Breast Cancer Cells | Q58377546 | ||
| An essential heparin-binding domain in the fibroblast growth factor receptor kinase | Q70619107 | ||
| Heparan sulphate in breast cancer cells | Q71701362 | ||
| Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ | Q73337621 | ||
| The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates | Q73914306 | ||
| Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? | Q73979803 | ||
| Fibroblast growth factor-2 has opposite effects on human breast cancer MCF-7 cell growth depending on the activation level of the mitogen-activated protein kinase pathway | Q77676593 | ||
| Tyrosine phosphorylation of syndecan-1 and -4 cytoplasmic domains in adherent B82 fibroblasts | Q77696893 | ||
| Signal transduction by fibroblast growth factor receptors | Q78171822 | ||
| Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma | Q78227067 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heparan sulfate proteoglycans | Q66589633 |
| P304 | page(s) | 185-94 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | The American Journal of Pathology | Q4744259 |
| P1476 | title | Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas | |
| P478 | volume | 160 |
| Q31114185 | A joint analysis of transcriptomic and metabolomic data uncovers enhanced enzyme-metabolite coupling in breast cancer |
| Q39657124 | A small oxazine compound as an anti-tumor agent: A novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-α |
| Q35535743 | Acquisition of anoikis resistance up-regulates syndecan-4 expression in endothelial cells. |
| Q35519929 | Agrin and perlecan mediate tumorigenic processes in oral squamous cell carcinoma. |
| Q61453755 | Anticancer Activity of Chitosan, Chitosan Derivatives, and Their Mechanism of Action |
| Q37941513 | Antithetic roles of proteoglycans in cancer. |
| Q43752663 | Association of heparan sulfate proteoglycans SDC1 and SDC4 polymorphisms with breast cancer in an Australian Caucasian population. |
| Q35768137 | Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans |
| Q24810282 | Clonogenic growth of human breast cancer cells co-cultured in direct contact with serum-activated fibroblasts |
| Q92258305 | Complete Response to a Fibroblast Growth Factor Receptor Inhibitor in a Patient With Head and Neck Squamous Cell Carcinoma Harboring FGF Amplifications |
| Q91752738 | Context-dependent regulation of receptor tyrosine kinases: Insights from systems biology approaches |
| Q38357653 | Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. |
| Q47240245 | Dually modified transmembrane proteoglycans in development and disease |
| Q33511333 | Effect of syndecan-1 overexpression on mesenchymal tumour cell proliferation with focus on different functional domains |
| Q43263196 | Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. |
| Q41444734 | Expression of syndecan-4 and correlation with metastatic potential in testicular germ cell tumours. |
| Q27851554 | FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer |
| Q33435680 | Gene set internal coherence in the context of functional profiling |
| Q64249445 | Glycosaminoglycans and Glycosaminoglycan Mimetics in Cancer and Inflammation |
| Q37983930 | Glycosaminoglycans: key players in cancer cell biology and treatment |
| Q24674858 | Glypican-1 is frequently overexpressed in human gliomas and enhances FGF-2 signaling in glioma cells |
| Q37105315 | Heparan sulfate and heparanase as modulators of breast cancer progression |
| Q34475894 | Heparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity |
| Q33596487 | Heparanase and hepatocellular carcinoma: promoter or inhibitor? |
| Q78725182 | Heparanase gene expression and its correlation with spontaneous apoptosis in hepatocytes of cirrhotic liver and carcinoma |
| Q31004886 | Heparanase-1 gene expression in normal, hyperplastic and neoplastic prostatic tissue |
| Q44524738 | High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. |
| Q79968177 | Immunohistochemical expression of heparan sulfate correlates with stromal cell proliferation in breast phyllodes tumors |
| Q40205392 | In vivo and in vitro degradation of heparan sulfate (HS) proteoglycans by HPR1 in pancreatic adenocarcinomas. Loss of cell surface HS suppresses fibroblast growth factor 2-mediated cell signaling and proliferation |
| Q28085548 | Insights into the key roles of proteoglycans in breast cancer biology and translational medicine |
| Q41437410 | Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B. |
| Q40484443 | Physiology and gene expression characteristics of carcinogen-initiated and tumor-transformed glial progenitor cells derived from the CNS of methylnitrosourea (MNU)-treated Sprague-Dawley rats |
| Q38170933 | Potential roles of vessel wall heparan sulfate proteoglycans in atherosclerosis. |
| Q42435671 | Prostaglandin F2alpha involves heparan sulphate sugar chains and FGFRs to modulate osteoblast growth and differentiation |
| Q36787608 | Proteoglycans in cancer biology, tumour microenvironment and angiogenesis |
| Q37636855 | Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions |
| Q38250158 | Roles of glycosaminoglycans and glycanmimetics in tumor progression and metastasis |
| Q34718195 | Roles of heparan-sulphate glycosaminoglycans in cancer |
| Q27336444 | Selectivity in glycosaminoglycan binding dictates the distribution and diffusion of fibroblast growth factors in the pericellular matrix. |
| Q52673419 | Sensitive method for glycosaminoglycan analysis of tissue sections. |
| Q40162051 | Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation |
| Q64266719 | Soluble Heparin and Heparan Sulfate Glycosaminoglycans Interfere with Sonic Hedgehog Solubilization and Receptor Binding |
| Q35754809 | Structural and functional changes in heparan sulfate proteoglycan expression associated with the myofibroblastic phenotype |
| Q37939096 | Structure and function of the skeletal muscle extracellular matrix |
| Q35441324 | Syndecan-1 and syndecan-4 are independent indicators in breast carcinoma |
| Q42808742 | Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis |
| Q26784262 | Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication |
| Q40262635 | Syndecan-1 regulates FGF8b responses in S115 mammary carcinoma cells |
| Q38189392 | Syndecans as modulators and potential pharmacological targets in cancer progression |
| Q24807364 | Syndecans in tumor cell adhesion and signaling |
| Q92137106 | Targeting Heparanase in Cancer: Inhibition by Synthetic, Chemically Modified, and Natural Compounds |
| Q55318767 | The GAG-specific branched peptide NT4 reduces angiogenesis and invasiveness of tumor cells. |
| Q64980488 | The Laminin-α1 Chain-Derived Peptide, AG73, Binds to Syndecans on MDA-231 Breast Cancer Cells and Alters Filopodium Formation. |
| Q88230827 | The extracellular matrix: Focus on oligodendrocyte biology and targeting CSPGs for remyelination therapies |
| Q34031745 | The motile breast cancer phenotype roles of proteoglycans/glycosaminoglycans |
| Q36359232 | The role of the extracellular matrix in angiogenesis in malignant glioma tumors |
Search more.